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Abstract
Background: Control of malaria in pregnant women is still a major challenge as it constitutes an important cause
of maternal and neonatal mortality. Mefloquine (MQ) has been used for malaria chemoprophylaxis in non-immune
travellers for several decades and it constitutes a potential candidate for intermittent preventive treatment in
pregnant women (IPTp).
Methods: The safety of MQ, including its safety in pregnancy, is controversial and a continuing subject of
debate. Published studies which evaluated the use of MQ for malaria prevention or treatment in pregnant
women and which reported data on drug tolerability and/or pregnancy outcomes have been reviewed
systematically.
Results: Eighteen articles fitted the inclusion criteria, only one study was double-blind and placebo controlled.
No differences were found in the risk of adverse pregnancy outcomes in women exposed to MQ compared to
those exposed to other anti-malarials or to the general population. MQ combined with artesunate seems to be
better tolerated than standard quinine therapy for treatment of non-severe falciparum malaria, but a MQ loading
dose (10 mg/kg) is associated with more dizziness compared with placebo. When used for IPTp, MQ (15 mg/kg)
may have more side effects than sulphadoxine- pyrimethamine.
Conclusions: In the published literature there are no indications that MQ use during pregnancy carries an
increased risk for the foetus. Ideally, the use of MQ to prevent malaria should be based on a risk-benefit analysis
of adverse effects against the risk of acquiring the infection. For this purpose double-blinded randomized controlled
trials in African pregnant women are much needed.
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Background
Malaria in pregnancy continues to be a global health prob-
lem, accounting for 15% of maternal deaths in some mal-
aria endemic regions [1,2]. It also contributes to low birth
weight (LBW) (<2,500 g), either through intrauterine
growth retardation or pre-term delivery and to the occur-
rence of severe anaemia in the mother [3-15]. The World
Health Organization (WHO) recommends a package of
interventions to prevent the consequences of malaria dur-
ing pregnancy in areas with stable transmission in sub-
Saharan Africa including the use of insecticide-treated
nets (ITNs), intermittent preventive treatment (IPT) with
sulphadoxine-pyrimethamine (SP) and effective case man-
agement of malaria and anaemia [16]. In October 2012,
the WHO policy recommendation on IPT in pregnancy
(ITPp) with SP was updated and IPTp with SP is now rec-
ommended at each scheduled antenatal care (ANC) visit
for pregnant women living in areas of moderate-to-high
malaria transmission, provided that each dose is separated
by at least a month [17]. The emergence of Plasmodium
falciparum parasites resistant to SP has raised concern
over the long-term efficacy and effectiveness of SP as IPTp
[18-21]. As a result, alternative drugs are being evaluated
for IPTp to replace SP in the short or the long term.
Mefloquine (MQ) has many of the characteristics
needed for an anti-malarial to replace SP for IPTp [22].
These include: 1) a long half-life (median between 14
and 28 days at curative doses and between 12 and
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17 days at prophylactic doses); 2) single dose administra-
tion; 3) a well-characterized pharmacokinetic profile in
pregnant women [23-25]; 4) infrequent MQ resistance
in Africa; and, 5) an acceptable reproductive toxicity
profile in animal studies. As a consequence, MQ is con-
sidered appropriate for chemoprophylaxis for pregnant
women travellers of all gestational ages to high risk areas
by various expert agencies such as the United States
(US) Centers for Disease Control and Prevention (CDC)
and the French Reference Centre on Teratogenic Agents
(CRAT) [26,27]. In addition, the drug was recently re-
classified as pregnancy category B (though initially
rated as C) by the US- Food and Drug Administration
(FDA) [28].
MQ was developed by the US Army in the late 1970s.
It belongs to the arylaminoalcohols group of anti-
malarial drugs and has blood schizonticidal properties
[29]. The most common adverse effects related to its use
are gastrointestinal and neurological. Severe central ner-
vous system side effects occur in about 1:10,000 travel-
lers taking MQ as chemoprophylaxis [30]. Risk factors
reported to be associated with MQ-induced neuro-
psychiatric adverse events include a previous history
of psychiatric problems, female sex, low body mass
index (BMI) and first-time use of the drug [31]. Meflo-
quine is contra-indicated in subjects with a history of
a neuropsychiatric illness, including epilepsy. The inci-
dence of adverse events is higher when MQ is admin-
istered at the recommended treatment dosage (25
milligram (mg)/ kilogram (kg)) as compared to lower
doses (15 mg/kg), suggesting a dose-related effect [32].
The frequency of adverse events is considerably lower
when the drug is used at prophylactic doses (250 mg/week)
than when it is used for treatment. Recently, the FDA has
released a safety communication raising concerns about
possible long-term psychiatric and neurological side effects
following MQ use [33]. The drug is currently one of the
most controversial anti-malarial medicines and the target
of various special interest groups following its massive
administration to US troops deployed in endemic areas
since 1992 [34].
In view of the potential use of MQ for IPTp in malaria-
endemic areas and existing concerns regarding its safety, a
systematic literature review on the safety of MQ when given
in pregnancy was carried out. The study included published
articles reporting data on the safety of MQ administered for
malaria treatment or prevention in pregnant women. This
review also provided a background paper for WHO’s Tech-
nical Expert Group on IPTp, which met in Geneva in July
2013 to consider the potential use of MQ for IPTp.
Methods
A comprehensive search for data on the safety of MQ in
pregnancy in medical databases (PubMed, the Cochrane
library, US National Institutes of Health Clinical Trials
data base [35], WHO library) was made, and non-
medical search engines were interrogated using “meflo-
quine”, “pregnancy” as keywords/search terms from April
to June 2013. Thirty-five abstracts were selected from
the 136 initially listed titles for further review. Special
consideration was given to original articles and system-
atic reviews but reports of case series were also included.
An additional search introducing “safety” as a search
term resulted in a further 25 articles for screening.
Additional references were obtained from references
provided in the articles identified through the search.
The current review focuses on the safety of MQ use in
pregnant women in terms of pregnancy outcomes and
drug tolerability. Criteria for inclusion in the review
were published articles written in English reporting re-
sults of studies that evaluated the safety of MQ (used
alone or combined with other anti-malarials) in pregnant
women for treatment and/or prevention of malaria. The
main findings and conclusions generated by all the studies
reviewed are organized by topic and the key parameters of
these studies are summarized in two tables.
Results
Figure 1 shows the flow diagram of the article selection
process. Eighteen articles which met the inclusion cri-
teria were included in the final selection: eight reported
safety data of MQ when used for malaria treatment
(Table 1) and ten evaluated MQ in pregnant women for
malaria prevention (See Additional file 1).
The safety of mefloquine when used for the treatment of
malaria in pregnancy
The first reports on the use of MQ in pregnant women
are from the late 1980s [36,37]. Most experience on its
use in treatment of malaria in pregnancy comes from
Southeast Asia where MQ was administered primarily in
combination with artesunate (AS) and where increasing
resistance to MQ has been reported [38,39]. In Thailand,
this combination (MQ-AS) was shown to be more ef-
fective than quinine (QN) in clearing parasites and
fever in pregnant women with uncomplicated malaria
[40,41]. Studies are currently on going in sub-Saharan
Africa to evaluate MQ-AS efficacy for malaria treat-
ment in pregnancy [42].
A non-randomized, comparative MQ treatment study
conducted in 372 pregnant women with uncomplicated
falciparum malaria in Thailand between 1991 and 1996
reported no differences in the rates of congenital anom-
alies and stillbirth among women who were treated with
a single dose of MQ (25 mg/kg; n = 194) and those
treated with QN for seven days (30 mg/kg/day; n = 93),
or MQ +QN (n = 85) [43]. The most common adverse
effects following MQ administration were dizziness (36%)
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and anorexia (23%) and the most common adverse effects
after QN were dizziness (42%) and tinnitus (35%). The
study was not blinded and the groups were not well
matched and thus findings on tolerability are of limited
value.
In 1999, a report was published on a retrospective ana-
lysis of the pregnancy outcomes of women exposed to
MQ in Thailand, based on ANC registries and self-
reported information from interviews [44]. This study
showed an increased risk of stillbirths in women treated
with 25 mg/kg of MQ (9/208, 4.5%) compared to those
treated with other anti-malarials (10/656 [1.6%] in those
exposed to QN, and 12/909 [1.4%] in those exposed to
other anti-malarials). Despite the fact that the study had
some limitations (such as possible recall bias and the
small number of stillbirths observed in the MQ group),
the article led CDC to recommend that MQ should not
be used for malaria treatment in pregnancy if other ef-
fective anti-malarial medicines were available, as well as
raising much general concern and open debate about
the safety of this drug in pregnancy. Harinasuta et al.
had previously reported no differences in the rates of
stillbirths between study groups in a small clinical trial
which had compared MQ (two doses of 500 mg, n = 85)
with QN (1800 mg for seven days, n =72) for the
treatment of multiresistant falciparum malaria in preg-
nant Thai women [45]. Another randomized study
from the same region in Thailand, which compared
MQ-AS (n = 54) with QN (n = 42) for the treatment of
falciparum malaria in pregnant women in the second
and third trimesters, found no differences in the rates
of congenital anomalies, stillbirths or birth weight be-
tween the treatment groups [40]. Those treated with
QN (10 mg/kg × 3 for seven days) compared with
those treated with MQ (15 mg/kg on day 1 + 10 mg/kg on
day 2) and AS (4 mg/kg/day for three days) had significantly
more dizziness (87 versus 45%) and tinnitus (66 versus 17%).
However, the study was not blinded and included only a
small number of women.
A small, non-comparative study (n = 40) conducted be-
tween 1998 and 2001 among Sudanese pregnant women
who presented with malaria after a full course of chloro-
quine (CQ) therapy and who were then treated with MQ
(25 mg/kg), concluded that MQ could be used safely dur-
ing the second and third trimesters of gestation as no
abortions, stillbirths or congenital anomalies were ob-
served [46]. The main complaints of recipients were nau-
sea and itching. In a similar, non-comparative study
undertaken in Nigeria, where a much lower MQ dose
(12.5 mg/kg) was used, only minimal side effects were
Figure 1 Diagram flow of articles selected.
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Table 1 Studies which evaluated the safety of mefloquine for treatment of malaria in pregnant women
Reference Study year
and location
Study design Study women MQ safety on pregnancy
outcomes
MQ tolerability Comments
Harinasuta
et al. 1990 [45]
Thailand Clinical trial which compared MQ
to QN for the treatment of
multi-resistant falciparum malaria
N = 85 women (all
trimesters) treated
with MQ vs N = 72
treated with QN
No differences in stillbirth
rates between groups
All mild and transient adverse
events.
Small sample size
Limited information on
procedures and results
available
Okeyeh et al.
1996 [47]
Nigeria Non comparative MQ treatment study
in pregnant women (12.5 mg/kg)
N = 33 women in 2nd
and 3rd trimester
No stillbirths and congenital
malformations reported
Minimal side effects Small sample size
Low dose of MQ used
Sowunmi et al.
1998 [49]
Nigeria Open label trial which compared
artemether to artemether +MQ
in the treatment of uncomplicated
malaria
N = 45 women in 2nd
and 3rd trimesters
No abortion, stillbirth or
congenital anomalies were
observed
Minimal adverse events reported
in the artemether – MQ group
(dizziness and abdominal pain)
in 2/45 patients
Small sample size
n = 23 artemether Open label trial
n = 22 artemether + MQ
McGready et al.
1998 [43]
1991-96 Non- randomized comparative MQ
treatment study, cohort series
N = 372 Similar rates of congenital
anomalies and stillbirths
among groups
The most common adverse effects
following MQ were dizziness (36%)
and anorexia (23%)
Open label cohort series
Groups not well matched
Thailand n = 194 treated with
MQ (in 2nd and 3rd
trimesters)
n = 93 treated with
QN
n = 85 MQ + QN
Nosten et al.
1999 [44]
1991-94 Retrospective analysis of the pregnancy
outcomes of women exposed to MQ
compared to those not exposed (based
on ANC registries and self-reported
information from interviews)
N = 208 pregnancies
exposed to MQ
(mainly 2nd and 3rd
trimesters) vs
Increased risk of reported
stillbirths in women exposed
to MQ:
No data available Analysis with several
limitations
Thailand N = 656 exposed to
QN vs
(9/208) 4.5% (MQ group) vs 1) Four women out of the
nine with a stillbirth had
been exposed to other
anti-malarials;N = 909 exposed to
other anti-malarials vs
(10/656) 1.6% (QN group) vs
N= 2,470 not exposed to
anti-malarials
(12/909) 1.4% (other
anti-malarials) vs
(40/2470) 1.8% (not exposed)
2) Recall bias possible (results
based on self-reported data)
McGready et al.
2000 [40]
1995-97 Open randomized comparison of
different malaria treatments in
pregnant women in the 2nd
and 3rd trimesters
N = 108 No differences in the rates of
congenital anomalies, stillbirths
or birth weight between the
treatment groups
No serious adverse effects were
reported
Small sample size
Thailand n = 42 QN 7 days Dizziness was more frequent in
the QN group than in the MQ
(87 vs 45%)
MQ combined with AS
vs Open label
n = 66 MQ (25 mg/kg) +
AS 3 days
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Table 1 Studies which evaluated the safety of mefloquine for treatment of malaria in pregnant women (Continued)
Bounyasong
2001 [48]
Thailand Open randomized comparison of
different malaria treatments in
pregnant women in the 2nd and 3rd
trimesters
N = 60 No data available QN group reported more adverse
effects than the MQ group (nausea,
vomiting, vertigo, tinnitus and
hypoglycaemia)
Small sample size
n = 29 QN 7 days vs MQ combined with AS
n = 28 AS +MQ Open label
3 Lost to follow-up
Adam et al.
2004 [46]
1998-2001 Prospective study which evaluated
the efficacy and safety of MQ in
women who presented with malaria
after a full course of CQ therapy
N = 40 No abortion, stillbirth and
congenital anomalies were
observed
35% reported nausea and 17.5%
itching
Small sample size
Sudan Pregnant women in
the 2nd or 3rd trimester
of gestation
Non comparative study
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reported [47]. Two additional, small, randomized but not
blinded P. falciparum treatment studies have been pub-
lished [48,49]. In a study from Nigeria (n = 45), intramuscu-
lar artemether for five days was compared with artemether
given in combination with MQ 15 mg/kg on the first two
days of treatment. Reported adverse effects were minimal
and all newborn babies were normal at birth [49]. The
second study from Thailand (n = 60) found that women
treated with standard QN regimen (10 mg/kg/day for
seven days) in the second to third trimester had signifi-
cantly more nausea, vomiting, vertigo tinnitus and
hypoglycaemia compared with those who received the
standard MQ (25 mg/kg) + AS regimen [48]. The phys-
ical and neurological developments of the babies in
this study were normal (followed up to 12 months after
delivery) and there were no congenital abnormalities.
The safety of mefloquine when used for the prevention of
malaria in pregnancy
One of the first reported studies on the use of MQ as
prophylaxis in pregnancy described a placebo-controlled,
double-blind trial conducted in 1987-90 in Thailand
[50]. This trial, which evaluated MQ efficacy (250 mg/kg
weekly) as malaria prophylaxis in pregnancy, enrolled
339 women in the second trimester of gestation in two
study phases. The first phase was conducted between
1987 and 1988 and enrolled 60 women in the MQ group
(they received an initial loading dose of 10 mg/kg before
starting weekly prophylaxis) and 59 in the placebo group.
The subsequent, second phase was conducted between
1989 and 1990 and enrolled 111 in the MQ group and
109 in the placebo arm. The MQ prophylactic dose used
was the standard 250 mg once weekly for the first four
weeks after which it was reduced to 125 mg once weekly
until delivery. Overall, the rates of abortions, congenital
anomalies, prematurity, and stillbirths were similar be-
tween groups. An increased risk of stillbirth was observed
in the MQ group (12.5 versus 0%) in the first phase of the
trial but this was not confirmed in the second phase. Dur-
ing the same period, pregnant women attending the same
ANC but not participating in the study had a 6.7% rate of
stillbirth. In the second phase, a weekly questionnaire,
which asked about 20 symptoms, was used. There were
no differences between the placebo and the MQ groups in
reported adverse events. In addition, there were no differ-
ences in terms of liver, renal, neurological, or cardiac
toxicity and no serious drug-related side effects were
reported. The only significant finding was that MQ
loading caused more transient dizziness than the pla-
cebo (28 versus 14%). The study concluded that MQ
was safe and effective in the second half of pregnancy
and that MQ prophylaxis was well tolerated.
During the same period, the Mangochi Malaria Re-
search Project compared four malaria preventive regimens
in pregnant Malawian women: 1) CQ treatment in an ini-
tial dose of 25 mg/kg followed by 300 mg weekly (n =
741); 2) CQ 25 mg/kg monthly (n = 1,459); 3) CQ 300 mg
weekly (n = 661); and, 4) MQ in an initial treatment dose
of 750 mg followed by 250 mg weekly (n = 932) [14,51,52].
This large, open-label trial enrolled 4,187 women and
found similar overall rates of reported adverse effects fol-
lowing each treatment, as well as similar rates of abortion
and stillbirth between groups. However, women who
received MQ reported less itching and more dizziness
compared to those who received CQ, although this
was a non-blinded study and significance testing was
not performed. The frequency of reported adverse
events was lower after the fourth dose than after the
first dose.
A subsequent analysis of a case series of 72 American
soldiers who took weekly MQ prophylaxis without prior
knowledge of their pregnancy showed a high frequency
of spontaneous abortion (12/72) [53]. However, the au-
thors considered that the high number of reported elect-
ive abortions (n = 17), losses to follow-up (n = 19) and
potential exposure to other stress factors could have in-
creased the rate of abortions in this particular popula-
tion. In addition, no control group was available for
comparison.
In 1998, a study of 1,627 reports of MQ exposure dur-
ing pregnancy received by the Roche post-marketing
surveillance system (mainly for chemoprophylaxis) be-
tween 1986 and 1996, reported a 4% prevalence of con-
genital malformations in infants of women in the cohort,
a prevalence similar to that found in the general popula-
tion [54]. The study included over 600 reports on MQ
exposure during the 1st trimester of gestation and it con-
cluded that MQ could be used in pregnant women for
prophylaxis. Phillips-Howard et al. also found no differ-
ence in the rates of adverse pregnancy outcomes among
women exposed to MQ (n = 99) compared to women ex-
posed to other anti-malarials (n = 137) in an analysis of
reported use of MQ during the first trimester of preg-
nancy in European travellers [55].
More recently, an open-label, randomized, controlled
trial (RCT) which compared MQ (15 mg/kg) with SP for
IPTp was conducted in HIV-negative, pregnant women
(805 in the MQ group and 804 in the SP) in Benin from
2005 to 2008 [22]. In this study, the incidence of spon-
taneous abortions (0.4% in MQ and 0.1% in the SP
group), stillbirths (2.8% in the MQ and 2% in the SP
group) and congenital anomalies (1% in the MQ and
0.5% in the SP group) did not differ significantly between
groups. On the other hand, based on a questionnaire
collected one week after drug intake, women who re-
ceived MQ had a much higher frequency of reported ad-
verse events than those who received SP: 52% vomiting
and 50% dizziness, compared to 12 and 13% in the SP
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group, respectively. Most of the symptoms were mild
and resolved quickly and spontaneously. The study was
not blinded, which makes tolerability assessment diffi-
cult. The authors also suggest a possible enhanced an-
ticipation of adverse events in the community where
discussions had been organized before the first adminis-
tration of IPTp.
A later analysis, which used data from the Beninese
RCT described above and from another IPTp-MQ open
trial, which compared MQ tolerability between HIV-
infected (n = 94) and uninfected pregnant women (n =
385), found that adverse events such as vomiting and
dizziness were less frequently reported in HIV-infected
women than in uninfected women (33 versus 56% and
39 versus 51%, respectively) [56]. In both studies, adverse
events were more frequent after the first IPTp-MQ than
at the second. However, this is a comparison between
two different, non-blinded studies using different proto-
cols and done during different time periods so validity of
this comparison must be interpreted with great caution.
A further analysis of 2,506 reports of MQ exposure
during pregnancy, mainly when used for chemoprophy-
laxis, from the F Hoffman-La Roche global drug safety
database has recently been published and concluded that
the prevalence of birth defects (4.4%) (43/978) and foetal
loss were comparable in women exposed to MQ in preg-
nancy to background rates of the general population
[57]. This analysis included part of the reports analyzed
previously by Phillips-Howard et al. [55].
Discussion
In spite of several decades of experience with the use of
MQ in the treatment of malaria, reports of only two
RCTs were found which specifically evaluated MQ safety
in pregnant women and only one of these was blind and
placebo controlled [22,50]. This may be due to the fact
that pregnant women are systematically excluded from
drug trials for ethical, legal and sociological concerns be-
cause of fear of toxicity to the foetus [29].
The evidence provided by one large but not random-
ized, nor blinded study suggests that the tolerability to
MQ when used as prophylaxis in pregnant women is
similar to that of CQ, although the risk of dizziness
might be higher with MQ [51]. The only randomized,
controlled, double-blind trial which compared MQ toler-
ability to placebo, did not find differences in the rates of
reported adverse effects between study arms in those
not given a MQ loading dose [50]. An interim WHO re-
port on MQ tolerability in pregnancy (Urban Hellgren,
unpublished) points out the need for blinded studies to
accurately estimate common and subjective side effects,
especially for evaluation of tolerability and side effects of
disputed medicines such as MQ [34,58]. This is particu-
larly the case when cases of serious adverse events are
disseminated widely in the general media. This may have
contributed to the considerable controversy among
international experts regarding the tolerability of MQ
prophylaxis versus alternative regimens in travellers [26].
In the IPTp randomized but not blinded trial conducted
in Benin, a dose of 15 mg of MQ was poorly tolerated
compared with SP, with higher frequencies of adverse
events such as vomiting and dizziness [22]. However,
when study participants are aware of the possibility of
specific adverse events either through the consent form
or through general knowledge of the drug, reporting
rates of those adverse events typically increase [59]. Such
knowledge is also likely to affect the evaluation of re-
latedness to the drug treatment by the investigator. In
this trial, it was observed that the frequency of related
adverse events decreased with increasing number of
doses, as in other studies of chemoprophylaxis with MQ
in pregnancy, but also in reports from travellers indicat-
ing that a true tolerance effect might play a role [26,51].
However, the incidence of adverse events reporting also
decreases with time in the placebo group in absence of
drug treatment [60,61].
Neuro-psychiatric adverse events (such as anxiety, de-
pression, behavioral changes, etc.) are difficult to assess
and monitor, especially in resource- constrained settings
where malaria is endemic. Thus it is possible that such
adverse events are underreported, which makes assess-
ment of these adverse events challenging. In addition,
malaria symptoms in pregnant women may be difficult
to distinguish from adverse events and consequently
relatedness to the drug may be particularly difficult to
assess [62].
Only a few small studies were found to have assessed
foetal safety of MQ when administered for malaria treat-
ment in pregnant women. Most of the safety data on
MQ use in pregnancy come from the post-marketing
surveillance system of the manufacturer (dominated by
exposure as chemoprophylaxis) and from retrospective
studies or studies from Southeast Asia [54,57,63,64].
There is a relative lack of safety studies on MQ treat-
ment in pregnant women in sub-Saharan Africa.
Concerns regarding a potential increased risk in the
rates of adverse pregnancy outcomes in women who
have received MQ during pregnancy constitute one of
the main controversial issues regarding MQ safety. How-
ever, the results from the single study, which reported an
association between MQ treatment and stillbirth in
Thailand [44] which initiated these concerns, have not been
confirmed in larger studies conducted in sub-Saharan
Africa [14,22]. Most of the identified studies included few
participants and were underpowered to appropriately assess
the risk of adverse pregnancy outcomes associated in preg-
nant women who had received MQ. A large, multicentre
RCT, which has evaluated the efficacy and safety of IPTp
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with MQ involving over 4,500 pregnant women has re-
cently finished and is expected to provide further important
information on MQ safety in pregnant women [65].
Only one article evaluating MQ safety in HIV-infected
pregnant women [56] was found. However, the results of
two small RCTs evaluating IPTp with MQ in HIV-
infected women from Benin which reported similar re-
sults have been published recently [66].
Considering the overlapping geographical distribution
of the HIV epidemic and malaria-endemic regions in
sub-Saharan Africa, it is essential that studies on treat-
ment and prevention of malaria in pregnancy include
HIV-infected women and that research on potential drug
interactions between anti-malarial drugs, including MQ,
and antiretroviral drugs is undertaken [67].
Conclusions
The use of MQ to prevent malaria in pregnancy should
be based on a risk-benefit analysis that balances the like-
lihood of adverse effects against the risk of acquiring the
infection, as is the case for other anti-malarials used in
pregnancy. Women’s acceptability of a particular drug
and their likely compliance also need to be considered
when the choice of an anti-malarial drug for use in preg-
nancy is being considered. Based on the evidence
reviewed, it can be concluded that MQ recipients did
not have an increased risk of adverse pregnancy out-
comes, including those in the first trimester of gestation.
There are only a few publications that have reported
on maternal MQ tolerability in pregnant women when
the drug has been used for malaria treatment, IPTp or
prophylaxis. MQ combined with AS seems to be better
tolerated than standard QN therapy for non-severe fal-
ciparum malaria but a MQ loading (10 mg/kg) dose is
associated with more dizziness compared with placebo.
When used for IPTp, MQ (15 mg/kg) may have more
side effects than SP but this needs to be confirmed in
double-blind randomized clinical trials.
There is a lack of RCTs evaluating MQ safety for mal-
aria treatment and prevention in African pregnant
women. Future trials should be designed to be double-
blind to enable an objective assessment of MQ tolerabil-
ity and need also to include HIV-infected women.
Additional file
Additional file 1: Table summarizing the studies that evaluated the
safety of mefloquine for the prevention of malaria in pregnant
women.
Abbreviations
ANC: Antenatal clinic; AS: Artesunate; BMI: Body mass index; CDC: Centers for
Disease Control and Prevention; CQ: Chloroquine; FDA: Food and Drug
Administration; IPTp: Intermittent preventive treatment in pregnancy;
ITNs: Insecticide treated nets; kg: kilogram; LBW: Low birth weight;
mg: Milligram; MQ: Mefloquine; QN: Quinine; RCT: Randomized controlled
trial; SP: Sulphadoxine-pyrimethamine; US: United States; WHO: World Health
Organization.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors met International Committee of Medical Journal Editors’ criteria
for authorship. RG and UH conducted the literature search and reviewed the
articles included. BG and CM participated in the review design and
methodology. RG wrote the draft manuscript. All authors revised the
manuscript critically, and read and approved the final manuscript.
Acknowledgements
The authors are grateful to Andrea Bosman and Golbahar Pahalavan for their
helpful comments and suggestions on the manuscript. The present work
was prepared as background paper for the WHO Expert Review Group (ERG)
meeting on IPTp held in WHO headquarters in Geneva, 9-11 July, 2013.
Author details
1Barcelona Centre for International Heath Research (CRESIB, Hospital
Clínic- Universitat de Barcelona), Rosselló 132, 4-2, Barcelona E-08036, Spain.
2Manhiça Health Research Centre (CISM), Maputo, Mozambique. 3Unit of
Infectious Diseases, Department of Medicine, Karolinska University Hospital
Huddinge, Karolinska Institutet, Stockholm, Sweden. 4Faculty of Infectious and
Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.
Received: 10 December 2013 Accepted: 24 February 2014
Published: 28 February 2014
References
1. Granja ACMF, Bergstrom S: Avoidability of maternal death in
Mozambique: audit and retrospective risk assessment in 106 consecutive
cases. Afr J Health Sci 2000, 7:83–87.
2. Menendez C, Bardaji A, Sigauque B, Romagosa C, Sanz S, Serra-Casas E,
Macete E, Berenguera A, David C, Dobano C, Naniche D, Mayor A, Ordi J,
Mandomando I, Aponte JJ, Mabunda S, Alonso PL: A randomized
placebo-controlled trial of intermittent preventive treatment in pregnant
women in the context of insecticide treated nets delivered through the
antenatal clinic. PLoS One 2008, 3:e1934.
3. Brabin BJ: An analysis of malaria in pregnancy in Africa. Bull World Health
Organ 1983, 61:1005–1016.
4. Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, Brabin B, Newman
RD: Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis
2007, 7:93–104.
5. Greenwood BM GA, Snow RW, Byass P, Bennett S, Hatib N`Jie AB: The
effects of malaria chemoprophylaxis given by traditional birth
attendantes on the course and outcome of pregnancy. Trans R Soc Trop
Med Hyg 1989, 83:589–594.
6. Guyatt HL, Snow RW: Impact of malaria during pregnancy on low birth
weight in sub-Saharan Africa. Clin Microbiol Rev 2004, 17:760–769. table of
contents.
7. Le Hesran JY, Fievet N, Thioulouse J, Personne P, Maubert B, M'Bidias S,
Etye'ale D, Cot M, Deloron P: Development of cellular immune responses
to Plasmodium falciparum blood stage antigens from birth to 36 months
of age in Cameroon. Acta Trop 2006, 98:261–269.
8. Menendez C, D'Alessandro U, ter Kuile FO: Reducing the burden of malaria
in pregnancy by preventive strategies. Lancet Infect Dis 2007, 7:126–135.
9. Menendez C, Mayor A: Congenital malaria: the least known consequence
of malaria in pregnancy. Semin Fetal Neonatal Med 2007, 12:207–213.
10. Menendez C, Ordi J, Ismail MR, Ventura PJ, Aponte JJ, Kahigwa E, Font F,
Alonso PL: The impact of placental malaria on gestational age and birth
weight. J Infect Dis 2000, 181:1740–1745.
11. Schwarz NG, Adegnika AA, Breitling LP, Gabor J, Agnandji ST, Newman RD,
Lell B, Issifou S, Yazdanbakhsh M, Luty AJ, Kremsner PG, Grobusch MP:
Placental malaria increases malaria risk in the first 30 months of life. Clin
Infect Dis 2008, 47:1017–1025.
12. DE Shulman CE, Bulmer JN: Malaria as a cause of severe anaemia in
pregnancy. Lancet 2002, 360:494.
González et al. Malaria Journal 2014, 13:75 Page 8 of 10
http://www.malariajournal.com/content/13/1/75
13. Steketee RW, Nahlen BL, Parise ME, Menendez C: The burden of malaria in
pregnancy in malaria-endemic areas. Am J Trop Med Hyg 2001, 64:28–35.
14. Steketee RW, Wirima JJ, Hightower AW, Slutsker L, Heymann DL, Breman JG:
The effect of malaria and malaria prevention in pregnancy on offspring
birthweight, prematurity, and intrauterine growth retardation in rural
Malawi. Am J Trop Med Hyg 1996, 55:33–41.
15. van Geertruyden JP, Thomas F, Erhart A, D'Alessandro U: The contribution
of malaria in pregnancy to perinatal mortality. Am J Trop Med Hyg 2004,
71:35–40.
16. WHO: A strategic framework for malaria prevention and control during
pregnancy in the African region. Geneva: World Health Organization; 2004.
AFR/MAL/04/01.
17. WHO: Intermittent Preventive Treatment of malaria in pregnancy using
Sulfadoxine-Pyrimethamine (IPTp-SP). Updated WHO Policy Recommendation.
Geneva: World Health Organization; 2012. http://www.who.int/malaria/
iptp_sp_updated_policy_recommendation_en_102012.pdf.
18. Iriemenam NC, Shah M, Gatei W, van Eijk AM, Ayisi J, Kariuki S, Vanden Eng J,
Owino SO, Lal AA, Omosun YO, Otieno K, Desai M, Ter Kuile FO, Nahlen B,
Moore J, Hamel MJ, Ouma P, Slutsker L, Shi YP: Temporal trends of
sulphadoxine-pyrimethamine (SP) drug-resistance molecular markers in
Plasmodium falciparum parasites from pregnant women in western Kenya.
Malar J 2012, 11:134.
19. Menendez C, Serra-Casas E, Scahill MD, Sanz S, Nhabomba A, Bardaji A,
Sigauque B, Cistero P, Mandomando I, Dobano C, Alonso PL, Mayor A: HIV
and placental infection modulate the appearance of drug-resistant
Plasmodium falciparum in pregnant women who receive intermittent
preventive treatment. Clin Infect Dis 2011, 52:41–48.
20. Mockenhaupt FP, Bedu-Addo G, Eggelte TA, Hommerich L, Holmberg V,
von Oertzen C, Bienzle U: Rapid increase in the prevalence of
sulfadoxine-pyrimethamine resistance among Plasmodium falciparum
isolated from pregnant women in Ghana. J Infect Dis 2008, 198:1545–1549.
21. Taylor SM, Antonia A, Feng G, Mwapasa V, Chaluluka E, Molyneux M, ter
Kuile FO, Rogerson SJ, Meshnick SR: Adaptive evolution and fixation of
drug-resistant Plasmodium falciparum genotypes in pregnancy-
associated malaria: 9-year results from the QuEERPAM study. Infect Genet
Evol 2012, 12:282–290.
22. Briand V, Bottero J, Noel H, Masse V, Cordel H, Guerra J, Kossou H, Fayomi B,
Ayemonna P, Fievet N, Massougbodji A, Cot M: Intermittent treatment for
the prevention of malaria during pregnancy in Benin: a randomized,
open-label equivalence trial comparing sulfadoxine-pyrimethamine with
mefloquine. J Infect Dis 2009, 200:991–1001.
23. Na Bangchang K, Davis TM, Looareesuwan S, White NJ, Bunnag D,
Karbwang J: Mefloquine pharmacokinetics in pregnant women with
acute falciparum malaria. Trans R Soc Trop Med Hyg 1994, 88:321–323.
24. Nosten F, Karbwang J, White NJ, Honeymoon N, Bangchang K, Bunnag D,
Harinasuta T: Mefloquine antimalarial prophylaxis in pregnancy: dose
finding and pharmacokinetic study. Br J Clin Pharmacol 1990, 30:79–85.
25. Ward SA, Sevene EJ, Hastings IM, Nosten F, McGready R: Antimalarial drugs
and pregnancy: safety, pharmacokinetics, and pharmacovigilance. Lancet
Infect Dis 2007, 7:136–144.
26. Schlagenhauf P, Adamcova M, Regep L, Schaerer MT, Rhein HG: The position of
mefloquine as a 21st century malaria chemoprophylaxis. Malar J 2010, 9:357.
27. Centre de Référence sur les Agents Tératogènes: Mefloquine. http://www.
lecrat.org/, [accessed February 2014].
28. FDA: New recommendations for mefloquine use in pregnancy. http://www.
cdc.gov/malaria/new_info/2011/mefloquine_pregnancy.html,
[accessed August 2013].
29. Sevene E, Gonzalez R, Menendez C: Current knowledge and challenges of
antimalarial drugs for treatment and prevention in pregnancy. Expert
Opin Pharmacother 2010, 11:1277–1293.
30. Steffen R, Fuchs E, Schildknecht J, Naef U, Funk M, Schlagenhauf P,
Phillips-Howard P, Nevill C, Sturchler D: Mefloquine compared with
other malaria chemoprophylactic regimens in tourists visiting east Africa.
Lancet 1993, 341:1299–1303.
31. van Riemsdijk MM, Sturkenboom MC, Ditters JM, Tulen JH, Ligthelm RJ,
Overbosch D, Stricker BH: Low body mass index is associated with an
increased risk of neuropsychiatric adverse events and concentration
impairment in women on mefloquine. Br J Clin Pharmacol 2004,
57:506–512.
32. ter Kuile FO, Nosten F, Thieren M, Luxemburger C, Edstein MD,
Chongsuphajaisiddhi T, Phaipun L, Webster HK, White NJ: High-dose
mefloquine in the treatment of multidrug-resistant falciparum malaria.
J Infect Dis 1992, 166:1393–1400.
33. FDA Drug Safety Communication: FDA approves label changes for
antimalarial drug mefloquine hydrochloride due to risk of serious psychiatric
and nerve effects. http://www.fda.gov/Drugs/DrugSafety/ucm362227.htm.
2013, [accessed July 2013].
34. Nevin RL: Limitations of postmarketing surveillance in the analysis of risk
of pregnancy loss associated with maternal mefloquine exposure. Clin
Infect Dis 2012, 55:1167–1168. author reply 1168-1169.
35. U.S. National Institutes of Health: Clinical Trials data base. http://clinicaltrials.
gov/, [accessed February 2014].
36. Collignon P, Hehir J, Mitchell D: Successful treatment of falciparum
malaria in pregnancy with mefloquine. Lancet 1989, 1:967.
37. Sweeney TR: The present status of malaria chemotherapy: mefloquine, a
novel antimalarial. Med Res Rev 1981, 1:281–301.
38. Carrara VI, Zwang J, Ashley EA, Price RN, Stepniewska K, Barends M,
Brockman A, Anderson T, McGready R, Phaiphun L, Proux S, van Vugt M,
Hutagalung R, Lwin KM, Phyo AP, Preechapornkul P, Imwong M,
Pukrittayakamee S, Singhasivanon P, White NJ, Nosten F: Changes in the
treatment responses to artesunate-mefloquine on the northwestern
border of Thailand during 13 years of continuous deployment. PLoS One
2009, 4:e4551.
39. Nosten F, van Vugt M, Price R, Luxemburger C, Thway KL, Brockman A,
McGready R, ter Kuile F, Looareesuwan S, White NJ: Effects of
artesunate-mefloquine combination on incidence of Plasmodium
falciparum malaria and mefloquine resistance in western Thailand: a
prospective study. Lancet 2000, 356:297–302.
40. McGready R, Brockman A, Cho T, Cho D, van Vugt M, Luxemburger C,
Chongsuphajaisiddhi T, White NJ, Nosten F: Randomized comparison of
mefloquine-artesunate versus quinine in the treatment of multidrug-resistant
falciparum malaria in pregnancy. Trans R Soc Trop Med Hyg 2000, 94:689–693.
41. Orton LC, Omari AA: Drugs for treating uncomplicated malaria in
pregnant women. Cochr Database Syst Rev (Online) 2008, 4:CD004912.
42. Clinicaltrials.gov: Safe and efficacious artemisinin-based combination
treatments for african pregnant women with malaria (PREGACT).
http://clinicaltrials.gov/ct2/show/NCT00852423 2010-14.
43. McGready R, Cho T, Hkirijaroen L, Simpson J, Chongsuphajaisiddhi T, White NJ,
Nosten F: Quinine and mefloquine in the treatment of multidrug-resistan
Plasmodium falciparum malaria in pregnancy. Ann Trop Med Parasit 1998,
92:643–653.
44. Nosten F, Vincenti M, Simpson J, Yei P, Thwai KL, de Vries A,
Chongsuphajaisiddhi T, White NJ: The effects of mefloquine treatment in
pregnancy. Clin Infect Dis 1999, 28:808–815.
45. Harinasuta T, Kietinun S, Somlaw S, Bunnag D, Sheth U, Wernsdorfer W:
A clinical trial of mefloquine on multi-resistant falciparum malaria in
pregnant women in Thailand. Bull Soc Fr Parasitol 1990:429.
46. Adam I, Ali DA, Alwaseila A, Kheir MM, Elbashir MI: Mefloquine in the
treatment of falciparum malaria during pregnancy in Eastern Sudan.
Saudi Med J 2004, 25:1400–1402.
47. Okeyeh JN, Lege-Oguntoye L, Emembolu JO, Agbo M: Malaria in
pregnancy: efficacy of a low dose of mefloquine in an area holoendemic
for multi-drug resistant Plasmodium falciparum. Ann Trop Med Parasit
1996, 90:265–268.
48. Bounyasong S: Randomized trial of artesunate and mefloquine in
comparison with quinine sulfate to treat P. falciparum malaria pregnant
women. J Med Assoc Thai 2001, 84:1289–1299.
49. Sowunmi A, Oduola AM, Ogundahunsi OA, Fehintola FA, Ilesanmi OA,
Akinyinka OO, Arowojolu AO: Randomised trial of artemether versus
artemether and mefloquine for the treatment of chloroquine/
sufadoxine-pyrimethamine-resistant falciparum malaria during
pregnancy. J Obstet Gynaecol 1998, 18:322–327.
50. Nosten F, ter Kuile F, Maelankiri L, Chongsuphajaisiddhi T, Nopdonrattakoon L,
Tangkitchot S, Boudreau E, Bunnag D, White NJ: Mefloquine prophylaxis
prevents malaria during pregnancy: a double-blind, placebo-controlled
study. J Infect Dis 1994, 169:595–603.
51. Steketee RW, Wirima JJ, Slutsker L, Khoromana CO, Heymann DL, Breman JG:
Malaria treatment and prevention in pregnancy: indications for use and
adverse events associated with use of chloroquine or mefloquine. Am J
Trop Med Hyg 1996, 55:50–56.
52. Steketee RW, Wirima JJ, Slutsker L, Roberts JM, Khoromana CO, Heymann DL,
Breman JG: Malaria parasite infection during pregnancy and at delivery in
González et al. Malaria Journal 2014, 13:75 Page 9 of 10
http://www.malariajournal.com/content/13/1/75
mother, placenta, and newborn: efficacy of chloroquine and mefloquine in
rural Malawi. Am J Trop Med Hyg 1996, 55:24–32.
53. Smoak BL, Writer JV, Keep LW, Cowan J, Chantelois JL: The effects of
inadvertent exposure of mefloquine chemoprophylaxis on pregnancy
outcomes and infants of US Army servicewomen. J Infect Dis 1997,
176:831–833.
54. Vanhauwere B, Maradit H, Kerr L: Post-marketing surveillance of
prophylactic mefloquine (Lariam) use in pregnancy. Am J Trop Med Hyg
1998, 58:17–21.
55. Phillips-Howard PA, Steffen R, Kerr L, Vanhauwere B, Schildknecht J, Fuchs E,
Edwards R: Safety of mefloquine and other antimalarial agents in the first
trimester of pregnancy. J Travel Med 1998, 5:121–126.
56. Denoeud-Ndam L, Clement MC, Briand V, Akakpo J, Agossou VK,
Atadokpede F, Dossou-Gbete L, Komongui DG, Afangnihoun A, Girard PM,
Zannou DM, Cot M: Tolerability of mefloquine intermittent preventive
treatment for malaria in HIV-infected pregnant women in Benin. J Acquir
Immune Defic Syndrom 2012, 61:64–72.
57. Schlagenhauf P, Blumentals WA, Suter P, Regep L, Vital-Durand G, Schaerer
MT, Boutros MS, Rhein HG, Adamcova M: Pregnancy and fetal outcomes
after exposure to mefloquine in the pre- and periconception period and
during pregnancy. Clin Infect Dis 2012, 54:e124–e131.
58. Nevin RL: Mefloquine gap junction blockade and risk of pregnancy loss.
Biol Reprod 2012, 87:65.
59. Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, Moher
D: Better reporting of harms in randomized trials: an extension of the
CONSORT statement. Ann Int Med 2004, 141:781–788.
60. Lutfullin A, Kuhlmann J, Wensing G: Adverse events in volunteers
participating in phase I clinical trials: a single-center five-year survey in
1,559 subjects. Int J Clin Pharmacol Ther 2005, 43:217–226.
61. Sibille M, Deigat N, Janin A, Kirkesseli S, Durand DV: Adverse events in
phase-I studies: a report in 1015 healthy volunteers. Eur J Clin Pharmacol
1998, 54:13–20.
62. Bardaji A, Sigauque B, Bruni L, Romagosa C, Sanz S, Mabunda S,
Mandomando I, Aponte J, Sevene E, Alonso PL, Menendez C: Clinical
malaria in African pregnant women. Malar J 2008, 7:27.
63. Newman RD, Parise ME, Slutsker L, Nahlen B, Steketee RW: Safety,
efficacy and determinants of effectiveness of antimalarial drugs
during pregnancy: implications for prevention programmes in
Plasmodium falciparum-endemic sub-Saharan Africa. Trop Med Int
Health 2003, 8:488–506.
64. Nosten FMR, d’Alessandro U, Bonell A, Verhoeff F, Menendez C, Mutabingwa
T, Brabin B: Antimalarial Drugs in Pregnancy: A Review. Curr Drug Saf
2006, 1:1–15.
65. Clinicaltrials.gov: Evaluation of alternative antimalarial drugs for malaria in
pregnancy (MiPPAD). http://clinicaltrials.gov/show/NCT00811421 2009-13.
66. Denoeud-Ndam L, Zannou DM, Fourcade C, Taron-Brocard C, Porcher R,
Atadokpede F, Komongui DG, Dossou-Gbete L, Afangnihoun A, Ndam NT,
Girard PM, Cot M: Cotrimoxazole prophylaxis versus mefloquine
intermittent preventive treatment to prevent malaria in HIV-infected
pregnant women: two randomized controlled trials. J Acquir Immune Defic
Syndrom 2014, 65:198–206.
67. Gonzalez R, Ataide R, Naniche D, Menendez C, Mayor A: HIV and malaria
interactions: where do we stand? Expert Rev Anti Infect Ther 2012,
10:153–165.
doi:10.1186/1475-2875-13-75
Cite this article as: González et al.: Mefloquine safety and tolerability in
pregnancy: a systematic literature review. Malaria Journal 2014 13:75. Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
González et al. Malaria Journal 2014, 13:75 Page 10 of 10
http://www.malariajournal.com/content/13/1/75
